My current strategy is Buy & Hold.
I always ask myself: “Which stock would I have no problem holding for the next 10 years?”
That’s why I like to buy undervalued companies that fit into this narrative.
I also sometimes look for short-term opportunities, like scalping hype stocks on the short side. But I do this carefully, since I don’t want to get trapped in a position I dislike. Imagine holding a hype stock that fails you either have to realize your loss or hope for a miracle. Or even worse: shorting a hype stock that rallies even more. Then you must decide whether to hold and risk more loss, or realize now and regret it if it drops the next day.
That’s why I only do hedged shorts with ATM calls:
- my exit time is predefined by the option maturity,
- my max loss is limited to the premium of the ATM call.
You can still roll after expiration if needed. Meanwhile, if something like GOOG drops, I have no problem holding it for the next decade, almost certainly generating long-term profit.
Tech / Broader Market (47.91%)
Even though I’m very biotech-focused, about half of my portfolio is in tech, since I like to buy strong companies like Google and just hold them long-term.
I also own BABA and some German dividend stocks, since I don’t want to be fully exposed to the U.S. market. Funny enough, BABA has actually been my best performer this month :D.
I really like Dell and HPE because both are server companies that still trade at relatively low valuations (due to margins). With the ongoing AI hype, I think they can benefit a lot especially HPE with the Juniper acquisition.
Positions:
- HPE (7.14%)
- IBM (6.30%)
- ALV IBIS (5.75%)
- CSCO (4.94%)
- GOOG (4.17%)
- AAPL (3.89%)
- BABA (3.88%)
- AMZN (3.82%)
- DTE IBIS (3.62%)
- DELL (3.14%)
- V (2.78%)
Biotech (40.6%)
Big Pharma / Large Caps (16.52%)
I especially like my TEVA position and I’m thinking of expanding it, since I believe the generics market will grow significantly in the coming years.
On the other hand, I’m not very happy with GILD. I might sell if I reach break-even.
Positions:
- TEVA (3.88%)
- SNY (3.83%)
- GILD (3.68%)
- MRK (1.99%)
- NVO (1.88%)
- BAYN IBIS (1.77%)
Established Biotechs / Mid Caps (24.08%)
Positions:
- BIIB (3.52%)
- INCY (3.41%)
- UTHR (3.31%)
- INVA (3.18%)
- EXEL (3.20%)
- JAZZ (3.09%)
- CORT (2.87%)
- BAS IBIS (2.16%)
Risky Bets (5.40%)
This is my “gambling” part 😅 a few stocks that currently generate little or no revenue or a typical "retail" stocks but have strong upcoming catalysts.
Since this is high risk, I limit my exposure here to max. 10% of the portfolio.
I especially like PGEN:
- Their drug literally saves patients from surgery, with no alternative available.
- If they fail to build a sales team, Big Pharma would likely acquire them.
- With a market cap of just ~$1B, a $2B+ buyout is realistic, since the research costs for developing a similar drug would exceed that number anyway.
Positions:
- DNLI (1.62%)
- PGEN (1.49%)
- VNDA (1.30%)
- OMER (1.10%)
ETF (3.00%)
- HMWD (3.00%)